Navigation Links
Denosumab reduces burden of giant-cell tumor of the bone
Date:9/21/2012

PHILADELPHIA Treatment with denosumab, a drug targeted against a protein that helps promote bone destruction, decreased the number of tumor giant cells in patients with giant-cell tumor of the bone, and increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"Giant-cell tumor of the bone is a rare tumor that affects mostly young people," said Sant P. Chawla, M.D., director of the Santa Monica Oncology Center, Santa Monica, Calif. "Radical surgery is currently the only treatment option. In our study, the use of denosumab allowed patients to avoid radical surgery and prevented recurrence. We hope that in the future, its use may make it possible to avoid surgery completely."

Giant-cell tumor of the bone is a benign tumor characterized by giant cells that are positive for the protein RANK ligand, which helps promote bone destruction. Currently, the only treatment option for patients with giant-cell tumor of the bone is surgery. However, patients who undergo surgery often have recurrent disease or significant morbidity, such as amputation. In addition, 25 to 30 percent of patients with this tumor have to undergo joint replacements.

Chawla and colleagues conducted this phase II study to explore the mechanism of action of denosumab, an inhibitor of RANK ligand, in the treatment of giant-cell tumor of the bone.

Twenty adult patients with recurrent or unresectable giant-cell tumor of the bone were treated with subcutaneous denosumab every four weeks. After treatment, all 20 of the patients had a decrease in giant cells of 90 percent or greater, an indicator of a reduction of tumor burden. In addition, results indicated that 65 percent of the patients had new bone growth in areas where the RANK ligand had previously caused bone destruction.

"A majority of patients with giant-cell tumor of the bone are young and have to get joint replacements, which last 15 to 20 years before a repeat surgery is needed," Chawla said. "Now, we hopefully can do minimal surgery, avoiding a joint replacement and recurrence."

One of the next steps in evaluating denosumab for giant-cell tumor of the bone is a much larger, multinational study that is currently enrolling patients. In addition, Chawla hopes to evaluate the use of denosumab as a presurgery, or neoadjuvant, treatment as well.

"In the future we hope to investigate giving the drug prior to surgery to see the effect it has, then remove the tumor and evaluate the pathological response," Chawla said.

This study was funded by Amgen.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
2. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
3. Automated breast ultrasound dramatically reduces physician interpretation time
4. NIH study finds sigmoidoscopy reduces colorectal cancer rates
5. Surgical removal of abdominal fat reduces skin cancer in mice
6. Long-term ICS use reduces pleural effusion in patients with CAP
7. Regional anesthesia reduces complications and death for hip fracture patients
8. Surgical sling reduces risk of weakened bladder control after prolapse surgery, U-M study says
9. Single embryo transfer reduces the risk of perinatal mortality in IVF
10. HPV vaccine reduces infection, even in unvaccinated
11. HIV drug reduces graft-vs.-host disease in bone marrow transplant patients, Penn study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... Petaluma, CA (PRWEB) , ... August 16, 2017 ... ... donate and distribute $100,000 in AED (Automated External Defibrillator) machines to their local ... an AED device from Arrow Benefits Group. AED machines are an integral part ...
(Date:8/16/2017)... ... ... of A Child” is the creation of published author, Pauline DiBenedetto. , “As my mother ... was in such great pain, my mother thought that her time has come. Once I ... I was about eight years old, when I had a vision of my own, that ...
(Date:8/15/2017)... Los Angeles, CA (PRWEB) , ... August 15, 2017 , ... The city of Los ... styles exist in harmony with “Cali Style”. LA’s Top Style List, a website that spotlights ... to help the public wear their wardrobe all year long. , According to the senior ...
(Date:8/15/2017)... ... August 15, 2017 , ... The V Foundation ... 19th Annual V Foundation Wine Celebration raised nearly $9 million for cancer research ... million in “Fund-A-Need” donations to support the study of BRCA mutation research in ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
(Date:7/26/2017)... Fla. , July 26, 2017 Sancilio ... enrollment of our clinical trial evaluating Altemia TM , ... Anemia (SCA) and Sickle Cell Disease (SCD). The SCOT ... evaluate the efficacy and safety of Altemia TM ... is conducted under US IND 125274. ...
(Date:7/24/2017)... N.Y. , July 24, 2017 IBM (NYSE: ... the Gartner Magic Quadrant for Solid-State Arrays (SSA) for the ... According to Gartner, "Vendors in the Leaders ... and Completeness of Vision. A vendor in the Leaders quadrant ... needed to drive the acceptance of new technologies. These vendors ...
Breaking Medicine Technology: